XENETIC BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
XENETIC BIOSCIENCES, INC. (XBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2026-08-06
- XENETIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-06-30 was 0.00 shares.
- XENETIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-03-31 was 0.00 shares.
- XENETIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-06-30 was 0.00 shares.
- XENETIC BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-03-31 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-12 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |